StageSeries E | Alive
Last Raised$4M | 7 yrs ago
About Avraham Pharmaceuticals
Avraham Pharmaceuticals is a pharmaceutical company developing products for treatment and/or prevention of neurodegenerative disorders. The company's lead product candidate, ladostigil, is in Phase 2 for Alzheimer's disease. Ladostigil is a multifunctional compound that combines proven anti-symptomatic mechanisms of action with neuroprotective mechanisms, and was designed to provide durable, broad symptomatic treatment outcomes and disease-modification.
Missing: Avraham Pharmaceuticals's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Avraham Pharmaceuticals's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Avraham Pharmaceuticals
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Avraham Pharmaceuticals is included in 1 Expert Collection, including Biopharma Tech.
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Latest Avraham Pharmaceuticals News
May 7, 2020
A new report on the worldwide Mild Cognitive Impairment Therapeutic Market, providing a glimpse of effective testing techniques. It provides an in depth description of the dynamic perspective of the market with different perspectives. This report summarizes the technologies which will help expand your business growth within the near future. things of the worldwide market at the worldwide and regional level is additionally described within the market report through geographical segmentation. Key Player Mentioned: ConSynance Therapeutics Inc, Eisai Co Ltd, Eli Lilly and Company, Ensol Biosciences Inc, Genzyme Corp, IntelGenx Corp, Krenitsky Pharmaceuticals Inc, Merck & Co Inc, Nanotherapeutics Inc, Neuron Biopharma SA, Pfizer Inc, Sage Therapeutics Inc, SBI Pharmaceuticals Co Ltd, Suven Life Sciences Ltd, Takeda Pharmaceutical Company Ltd, Therapix Biosciences Ltd The Mild Cognitive Impairment Therapeutic Market may be a comprehensive description of the market and expects to point out some very nice growth over subsequent few years. This report provides an in-depth analysis of the present and future market prospects. This report is meant to assist readers within the region who are expected to grow the fastest during the forecast period. Alongside this, this compilation is meant to assist readers thoroughly analyze the recent trends, competitive environment within the global market during the forecast period. Product Segment Analysis: BAN-2401, Bosutinib, Brexanolone, CSP-1103, Others Application Segment Analysis: Hospital, Clinic, Others Regional Segment Analysis: United States, China, Europe, Japan, Southeast Asia, India This strategy are often employed by impending participants to extend penetration of the Mild Cognitive Impairment Therapeutic Market. The worldwide market has also been reviewed in terms of revenue. Market dynamics like market revenues, challenges, opportunities, and trends were given one-to-one impact analysis. Impact analysis helps to collect statistics on the longer term growth of the market. The research report provides an in-depth explanation of the varied factors that are likely to steer the market. Learn historical details to elucidate the future of the market. Analysts have studied the ever-changing market dynamics to assess their impact on the general market. The report also discusses the sectors that exist within the market. Influence of the Mild Cognitive Impairment Therapeutic Market report: - A Comprehensive assessment of all opportunities and risk within the Mild Cognitive Impairment Therapeutic Market. - Recent innovations and major events. - an in depth study of the business strategy for the expansion of the player leading the Mild Cognitive Impairment Therapeutic Market. - A definitive study of the market's growth plot over subsequent few years. - Facilitating important technologies and market latest trends that hit the market. About Us: Introspective Market Research is a visionary research company who is ready to assist their customer to flourish their business by offering strategies for gaining success. We sell market research reports received from other leading companies in the market research industry which offer in-depth and trustworthy information on different topics and sectors. The IMR founded by the team of experts and experienced professionals in the industry. The team is focusing on offering the empirical data collected from experts that can be the base for the next few years. The Aim of the company is to offering reports from numerous sectors such as FMCG, technology, food beverages, media, chemical, and healthcare among others. Contact Us:
Avraham Pharmaceuticals Frequently Asked Questions (FAQ)
Where is Avraham Pharmaceuticals's headquarters?
Avraham Pharmaceuticals's headquarters is located at 42 Hayarkon st, Yavneh.
What is Avraham Pharmaceuticals's latest funding round?
Avraham Pharmaceuticals's latest funding round is Series E.
How much did Avraham Pharmaceuticals raise?
Avraham Pharmaceuticals raised a total of $26.2M.
Who are the investors of Avraham Pharmaceuticals?
Investors of Avraham Pharmaceuticals include Clal Biotechnology Industries, Yissum Technology Transfer, Pontifax, Technion Research & Development Foundation, Integra Holdings and 3 more.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.